Daewoong Pharma (KO:069620) — Market Cap & Net Worth
Market Cap & Net Worth: Daewoong Pharma (069620)
Daewoong Pharma (KO:069620) has a market capitalization of $944.29 Million (₩1.39 Trillion) as of June 19, 2026. Listed on the KO stock exchange, this Korea-based company holds position #9314 globally and #251 in its home market, demonstrating a 0.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Daewoong Pharma's stock price ₩121100.00 by its total outstanding shares 11506270 (11.51 Million). Review 069620 total liabilities to assess the company's total debt and financial obligations.
Daewoong Pharma Market Cap History: 2015 to 2026
Daewoong Pharma's market capitalization history from 2015 to 2026. Data shows growth from $536.76 Million to $944.29 Million (4.99% CAGR).
Daewoong Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Daewoong Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Daewoong Pharma's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.04x
Daewoong Pharma's market cap is 0.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $536.76 Million | $839.69 Billion | $42.93 Billion | 0.00x | 0.01x |
| 2016 | $523.17 Million | $883.92 Billion | $26.97 Billion | 0.00x | 0.02x |
| 2017 | $1.26 Billion | $960.31 Billion | $31.58 Billion | 0.00x | 0.04x |
| 2018 | $1.45 Billion | $1.03 Trillion | -$15.15 Billion | 0.00x | N/A |
| 2019 | $1.06 Billion | $1.11 Trillion | $22.01 Billion | 0.00x | 0.05x |
| 2020 | $1.28 Billion | $1.06 Trillion | $12.75 Billion | 0.00x | 0.10x |
| 2021 | $1.15 Billion | $1.15 Trillion | $24.66 Billion | 0.00x | 0.05x |
| 2022 | $1.24 Billion | $1.28 Trillion | $42.24 Billion | 0.00x | 0.03x |
| 2023 | $910.76 Million | $1.38 Trillion | $121.74 Billion | 0.00x | 0.01x |
| 2024 | $985.62 Million | $1.42 Trillion | $24.73 Billion | 0.00x | 0.04x |
Competitor Companies of 069620 by Market Capitalization
Companies near Daewoong Pharma in the global market cap rankings as of June 19, 2026.
Key companies related to Daewoong Pharma by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Daewoong Pharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Daewoong Pharma's market cap moved from $536.76 Million to $ 944.29 Million, with a yearly change of 4.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩944.29 Million | -29.72% |
| 2025 | ₩1.34 Billion | +36.31% |
| 2024 | ₩985.62 Million | +8.22% |
| 2023 | ₩910.76 Million | -26.31% |
| 2022 | ₩1.24 Billion | +7.51% |
| 2021 | ₩1.15 Billion | -9.94% |
| 2020 | ₩1.28 Billion | +20.47% |
| 2019 | ₩1.06 Billion | -26.73% |
| 2018 | ₩1.45 Billion | +14.98% |
| 2017 | ₩1.26 Billion | +140.40% |
| 2016 | ₩523.17 Million | -2.53% |
| 2015 | ₩536.76 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Daewoong Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $944.29 Million USD |
| MoneyControl | $944.29 Million USD |
| MarketWatch | $944.29 Million USD |
| marketcap.company | $944.29 Million USD |
| Reuters | $944.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more